Trial Profile
Pilot Phase 1/2, Open-Label, Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs CT-38 (Primary)
- Indications Chronic fatigue syndrome; Encephalomyelitis
- Focus Therapeutic Use
- Acronyms InTiME
- 02 Sep 2021 According to Cortene media release, results from this trial have been peer reviewed and published in Frontiers in Systems Neuroscience,
- 02 Sep 2021 Results published in the Cortene Media Release
- 12 Jul 2019 Status changed from recruiting to completed.